In BCG treatment, the mechanisms of immune-escape are diverse, including the loss of MHC-I [62] or the up-regulation of PD-L1 and the poliovirus receptor (PVR or CD155) in tumor cells [63,64]. Here, PVR is linked to neoplasm.